These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33191280)

  • 41. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
    Gremese E; Ciccia F; Selmi C; Cuomo G; Foti R; Matucci-Cerinic M; Conti F; Fusaro E; Guggino G; Iannone F; Delle Sedie A; Perricone R; Idolazzi L; Moscato P; Theander E; Noël W; Bergmans P; Marelli S; Gossec L; Smolen JS;
    Clin Exp Rheumatol; 2023 Mar; 41(3):735-743. PubMed ID: 36226614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
    Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
    Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
    J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
    de Jong HMY; van Mens LJJ; Nurmohamed MT; Kok MR; van Kuijk AWR; Baeten DLP; van de Sande MGH
    Arthritis Res Ther; 2019 Sep; 21(1):208. PubMed ID: 31521192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
    Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
    Lindqvist U; Wernroth ML; Husmark T; Larsson P; Geijer M; Teleman A; Theander E; Alenius GM
    Clin Exp Rheumatol; 2017; 35(6):936-942. PubMed ID: 28628468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Joint tenderness and swelling in biologic-treated inflammatory arthritis patients - a tricky trade off?
    Harty LC; Ng CT; Fearon C; Murray CA; Fitzgerald O; Veale DJ
    Int J Clin Pract; 2012 Feb; 66(2):128-31. PubMed ID: 22257038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
    Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
    BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
    Mori Y; Kuwahara Y; Chiba S; Itoi E
    Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis.
    Orbai AM; Gladman DD; Goto H; Birt JA; Gellett AM; Lin CY; Kvien TK
    Clin Exp Rheumatol; 2021; 39(2):329-336. PubMed ID: 32573426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
    Eviatar T; Zisman D; Gendelman O; Reitblat T; Balbir-Gurman A; Mashiach T; Almog R; Elkayam O
    Clin Exp Rheumatol; 2022 Jan; 40(1):15-23. PubMed ID: 33427613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland.
    Thorsteinsson B; Geirsson AJ; Krogh NS; Gudbjornsson B;
    J Rheumatol; 2020 Oct; 47(10):1575-1581. PubMed ID: 32007931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey.
    Rifbjerg-Madsen S; Christensen AW; Christensen R; Hetland ML; Bliddal H; Kristensen LE; Danneskiold-Samsøe B; Amris K
    PLoS One; 2017; 12(7):e0180014. PubMed ID: 28686639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.